Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). - Strober, Bruce; Bachelez, Hervé; Crowley, Jeffrey; Elewski, Boni E.; Gooderham, Melinda; Menter, Alan; Strohal, Robert; Chen, Michael M.; Wu, Tianshuang; Zhan, Tianyu; Photowala, Huzefa; Armstrong, April (Journal of the European Academy of Dermatology & Venereology, 2024)